1
|
Scotton WJ, Shand C, Todd EG, Bocchetta M, Cash DM, VandeVrede L, Heuer HW, Young AL, Oxtoby N, Alexander DC, Rowe JB, Morris HR, Boxer AL, Rohrer JD, Wijeratne PA. Distinct spatiotemporal atrophy patterns in corticobasal syndrome are associated with different underlying pathologies. medRxiv 2024:2024.03.14.24304298. [PMID: 38562801 PMCID: PMC10984071 DOI: 10.1101/2024.03.14.24304298] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/04/2024]
Abstract
Objective To identify imaging subtypes of the cortico-basal syndrome (CBS) based solely on a data-driven assessment of MRI atrophy patterns, and investigate whether these subtypes provide information on the underlying pathology. Methods We applied Subtype and Stage Inference (SuStaIn), a machine learning algorithm that identifies groups of individuals with distinct biomarker progression patterns, to a large cohort of 135 CBS cases (52 had a pathological or biomarker defined diagnosis) and 252 controls. The model was fit using volumetric features extracted from baseline T1-weighted MRI scans and validated using follow-up MRI. We compared the clinical phenotypes of each subtype and investigated whether there were differences in associated pathology between the subtypes. Results SuStaIn identified two subtypes with distinct sequences of atrophy progression; four-repeat-tauopathy confirmed cases were most commonly assigned to the Subcortical subtype (83% of CBS-PSP and 75% of CBS-CBD), while CBS-AD was most commonly assigned to the Fronto-parieto-occipital subtype (81% of CBS-AD). Subtype assignment was stable at follow-up (98% of cases), and individuals consistently progressed to higher stages (100% stayed at the same stage or progressed), supporting the model's ability to stage progression. Interpretation By jointly modelling disease stage and subtype, we provide data-driven evidence for at least two distinct and longitudinally stable spatiotemporal subtypes of atrophy in CBS that are associated with different underlying pathologies. In the absence of sensitive and specific biomarkers, accurately subtyping and staging individuals with CBS at baseline has important implications for screening on entry into clinical trials, as well as for tracking disease progression.
Collapse
Affiliation(s)
- W J Scotton
- Dementia Research Centre, Department of Neurodegenerative Disease, University College London Queen Square Institute of Neurology, University College London, London, UK
| | - C Shand
- Centre for Medical Image Computing, Department of Computer Science, University College London, London, UK
| | - E G Todd
- Dementia Research Centre, Department of Neurodegenerative Disease, University College London Queen Square Institute of Neurology, University College London, London, UK
| | - M Bocchetta
- Dementia Research Centre, Department of Neurodegenerative Disease, University College London Queen Square Institute of Neurology, University College London, London, UK
- Centre for Cognitive and Clinical Neuroscience, Division of Psychology, Department of Life Sciences, College of Health, Medicine and Life Sciences, Brunel University London, London, UK
| | - D M Cash
- Dementia Research Centre, Department of Neurodegenerative Disease, University College London Queen Square Institute of Neurology, University College London, London, UK
| | - L VandeVrede
- Department of Neurology, Memory and Aging Center, University of California, San Francisco, CA, USA
| | - H W Heuer
- Department of Neurology, Memory and Aging Center, University of California, San Francisco, CA, USA
| | - A L Young
- Centre for Medical Image Computing, Department of Computer Science, University College London, London, UK
| | - N Oxtoby
- Centre for Medical Image Computing, Department of Computer Science, University College London, London, UK
| | - D C Alexander
- Centre for Medical Image Computing, Department of Computer Science, University College London, London, UK
| | - J B Rowe
- Cambridge University Department of Clinical Neurosciences and Cambridge University Hospitals NHS Trust
- Medical Research Council Cognition and Brain Sciences Unit, Cambridge UK
| | - H R Morris
- Department of Clinical and Movement Neurosciences, University College London Queen Square Institute of Neurology, London, UK
- Movement Disorders Centre, University College London Queen Square Institute of Neurology, London, UK
| | - A L Boxer
- Centre for Cognitive and Clinical Neuroscience, Division of Psychology, Department of Life Sciences, College of Health, Medicine and Life Sciences, Brunel University London, London, UK
| | - J D Rohrer
- Dementia Research Centre, Department of Neurodegenerative Disease, University College London Queen Square Institute of Neurology, University College London, London, UK
| | - P A Wijeratne
- Centre for Medical Image Computing, Department of Computer Science, University College London, London, UK
- Department of Informatics, University of Sussex, Brighton, BN1 9RH, UK
| |
Collapse
|
2
|
Casaletto KB, Staffaroni AM, Wolf A, Appleby B, Brushaber D, Coppola G, Dickerson B, Domoto-Reilly K, Elahi FM, Fields J, Fong JC, Forsberg L, Ghoshal N, Graff-Radford N, Grossman M, Heuer HW, Hsiung GY, Huey ED, Irwin D, Kantarci K, Kaufer D, Kerwin D, Knopman D, Kornak J, Kramer JH, Litvan I, Mackenzie IR, Mendez M, Miller B, Rademakers R, Ramos EM, Rascovsky K, Roberson ED, Syrjanen JA, Tartaglia MC, Weintraub S, Boeve B, Boxer AL, Rosen H, Yaffe K. Active lifestyles moderate clinical outcomes in autosomal dominant frontotemporal degeneration. Alzheimers Dement 2020; 16:91-105. [PMID: 31914227 PMCID: PMC6953618 DOI: 10.1002/alz.12001] [Citation(s) in RCA: 26] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2019] [Revised: 07/31/2019] [Accepted: 09/09/2019] [Indexed: 11/08/2022]
Abstract
INTRODUCTION Leisure activities impact brain aging and may be prevention targets. We characterized how physical and cognitive activities relate to brain health for the first time in autosomal dominant frontotemporal lobar degeneration (FTLD). METHODS A total of 105 mutation carriers (C9orf72/MAPT/GRN) and 69 non-carriers reported current physical and cognitive activities at baseline, and completed longitudinal neurobehavioral assessments and brain magnetic resonance imaging (MRI) scans. RESULTS Greater physical and cognitive activities were each associated with an estimated >55% slower clinical decline per year among dominant gene carriers. There was also an interaction between leisure activities and frontotemporal atrophy on cognition in mutation carriers. High-activity carriers with frontotemporal atrophy (-1 standard deviation/year) demonstrated >two-fold better cognitive performances per year compared to their less active peers with comparable atrophy rates. DISCUSSION Active lifestyles were associated with less functional decline and moderated brain-to-behavior relationships longitudinally. More active carriers "outperformed" brain volume, commensurate with a cognitive reserve hypothesis. Lifestyle may confer clinical resilience, even in autosomal dominant FTLD.
Collapse
Affiliation(s)
- K B Casaletto
- Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, California, USA
| | - A M Staffaroni
- Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, California, USA
| | - A Wolf
- Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, California, USA
| | - B Appleby
- Case Western Reserve University, Cleveland, Ohio, USA
| | | | - G Coppola
- University of California, Los Angeles, California, USA
| | - B Dickerson
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | | | - F M Elahi
- Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, California, USA
| | - J Fields
- Mayo Clinic, Rochester, Minnesota, USA
| | - J C Fong
- Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, California, USA
| | - L Forsberg
- Case Western Reserve University, Cleveland, Ohio, USA
| | - N Ghoshal
- Washington University, St. Louis, Illinois, USA
| | | | - M Grossman
- University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - H W Heuer
- Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, California, USA
| | - G-Y Hsiung
- University of British Columbia, Vancouver, British Columbia, Canada
| | - E D Huey
- Columbia University, New York, New York, USA
| | - D Irwin
- University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | | | - D Kaufer
- University of North Carolina, Chapel Hill, North Carolina, USA
| | - D Kerwin
- University of Texas Southwestern, Dallas, Texas, USA
| | - D Knopman
- Mayo Clinic, Rochester, Minnesota, USA
| | - J Kornak
- Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA
| | - J H Kramer
- Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, California, USA
| | - I Litvan
- Parkinson and Other Movement Disorder Center, Department of Neuroscience, University of California, San Diego, San Diego, California, USA
| | - I R Mackenzie
- University of British Columbia, Vancouver, British Columbia, Canada
| | - M Mendez
- University of California, Los Angeles, California, USA
| | - B Miller
- Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, California, USA
| | | | - E M Ramos
- University of California, Los Angeles, USA
| | - K Rascovsky
- University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | | | | | | | - S Weintraub
- Mesulam Center for Cognitive Neurology and Alzheimer's Disease, Northwestern University, Chicago, Illinois, USA
| | - B Boeve
- Mayo Clinic, Rochester, Minnesota, USA
| | - A L Boxer
- Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, California, USA
| | - H Rosen
- Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, California, USA
| | - K Yaffe
- Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, California, USA
- San Francisco Department of Psychiatry, University of California, San Francisco, California, USA
| |
Collapse
|
3
|
Hellmuth J, Mirsky J, Heuer HW, Matlin A, Jafari A, Garbutt S, Widmeyer M, Berhel A, Sinha L, Miller BL, Kramer JH, Boxer AL. Multicenter validation of a bedside antisaccade task as a measure of executive function. Neurology 2012; 78:1824-31. [PMID: 22573640 DOI: 10.1212/wnl.0b013e318258f785] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
OBJECTIVE To create and validate a simple, standardized version of the antisaccade (AS) task that requires no specialized equipment for use as a measure of executive function in multicenter clinical studies. METHODS The bedside AS (BAS) task consisted of 40 pseudorandomized AS trials presented on a laptop computer. BAS performance was compared with AS performance measured using an infrared eye tracker in normal elders (NE) and individuals with mild cognitive impairment (MCI) or dementia (n = 33). The neuropsychological domain specificity of the BAS was then determined in a cohort of NE, MCI, and dementia (n = 103) at UCSF, and the BAS was validated as a measure of executive function in a 6-center cohort (n = 397) of normal adults and patients with a variety of brain diseases. RESULTS Performance on the BAS and laboratory AS task was strongly correlated and BAS performance was most strongly associated with neuropsychological measures of executive function. Even after controlling for disease severity and processing speed, BAS performance was associated with multiple assessments of executive function, most strongly the informant-based Frontal Systems Behavior Scale. CONCLUSIONS The BAS is a simple, valid measure of executive function in aging and neurologic disease.
Collapse
Affiliation(s)
- J Hellmuth
- Department of Neurology, Memory and Aging Center, University of California, San Francisco, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|